1 Min Read
Sept 11 (Reuters) - Cymabay Therapeutics Inc
* CymaBay Therapeutics granted EMA orphan drug designation for seladelpar for the treatment of primary biliary cholangitis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.